Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Specific contribution of p19(ARF) to nitric oxide-dependent apoptosis.

Zeini M, Través PG, López-Fontal R, Pantoja C, Matheu A, Serrano M, Boscá L, Hortelano S.

J Immunol. 2006 Sep 1;177(5):3327-36. Erratum in: J Immunol. 2007 Jul 15;179(2):1389.

2.

TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort.

Murray L, Sedo A, Scott M, McManus D, Sloan JM, Hardie LJ, Forman D, Wild CP.

Gut. 2006 Oct;55(10):1390-7. Epub 2006 May 8.

3.

Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence.

Anderson LA, Johnston BT, Watson RG, Murphy SJ, Ferguson HR, Comber H, McGuigan J, Reynolds JV, Murray LJ.

Cancer Res. 2006 May 1;66(9):4975-82.

4.

Genetic clonal diversity predicts progression to esophageal adenocarcinoma.

Maley CC, Galipeau PC, Finley JC, Wongsurawat VJ, Li X, Sanchez CA, Paulson TG, Blount PL, Risques RA, Rabinovitch PS, Reid BJ.

Nat Genet. 2006 Apr;38(4):468-73. Epub 2006 Mar 26.

PMID:
16565718
5.

Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study.

Vaughan TL, Dong LM, Blount PL, Ayub K, Odze RD, Sanchez CA, Rabinovitch PS, Reid BJ.

Lancet Oncol. 2005 Dec;6(12):945-52.

PMID:
16321762
6.

Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications.

Hampel H, Abraham NS, El-Serag HB.

Ann Intern Med. 2005 Aug 2;143(3):199-211.

PMID:
16061918
7.

Natural selection in neoplastic progression of Barrett's esophagus.

Maley CC, Reid BJ.

Semin Cancer Biol. 2005 Dec;15(6):474-83. Review.

PMID:
16043360
8.

Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial.

Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE.

JAMA. 2005 Jul 6;294(1):47-55.

PMID:
15998890
9.
10.

INK4a/ARF: a multifunctional tumor suppressor locus.

Sharpless NE.

Mutat Res. 2005 Aug 25;576(1-2):22-38. Review.

PMID:
15878778
11.

Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk.

Schulmann K, Sterian A, Berki A, Yin J, Sato F, Xu Y, Olaru A, Wang S, Mori Y, Deacu E, Hamilton J, Kan T, Krasna MJ, Beer DG, Pepe MS, Abraham JM, Feng Z, Schmiegel W, Greenwald BD, Meltzer SJ.

Oncogene. 2005 Jun 9;24(25):4138-48.

PMID:
15824739
12.

Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention.

Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN.

J Clin Oncol. 2005 Jan 10;23(2):254-66. Review.

PMID:
15637389
13.

A COX-2 inhibitor prevents the esophageal inflammation-metaplasia-adenocarcinoma sequence in rats.

Oyama K, Fujimura T, Ninomiya I, Miyashita T, Kinami S, Fushida S, Ohta T, Koichi M.

Carcinogenesis. 2005 Mar;26(3):565-70. Epub 2004 Nov 25.

PMID:
15564290
14.

The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma.

Maley CC, Galipeau PC, Li X, Sanchez CA, Paulson TG, Blount PL, Reid BJ.

Cancer Res. 2004 Oct 15;64(20):7629-33.

15.

Focus on Barrett's esophagus and esophageal adenocarcinoma.

Paulson TG, Reid BJ.

Cancer Cell. 2004 Jul;6(1):11-6. Review. No abstract available.

16.

Pathways of urothelial cancer progression suggested by Bayesian network analysis of allelotyping data.

Bulashevska S, Szakacs O, Brors B, Eils R, Kovacs G.

Int J Cancer. 2004 Jul 20;110(6):850-6.

17.

Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus.

Maley CC, Galipeau PC, Li X, Sanchez CA, Paulson TG, Reid BJ.

Cancer Res. 2004 May 15;64(10):3414-27.

18.

Chromosomal gains and genomic loss of p53 and p16 genes in Barrett's esophagus detected by fluorescence in situ hybridization of cytology specimens.

Fahmy M, Skacel M, Gramlich TL, Brainard JA, Rice TW, Goldblum JR, Connor JT, Casey G, Legator MS, Tubbs RR, Falk GW.

Mod Pathol. 2004 May;17(5):588-96.

19.

Biomarkers of esophageal adenocarcinoma and Barrett's esophagus.

McManus DT, Olaru A, Meltzer SJ.

Cancer Res. 2004 Mar 1;64(5):1561-9. Review.

20.

Principles of tumor suppression.

Sherr CJ.

Cell. 2004 Jan 23;116(2):235-46. Review.

Supplemental Content

Support Center